Melanoma & Skin Cancer | Specialty

An Instinct for Innovation Drives Robert's Melanoma Research

September 7th 2019

A 2018 Giants of Cancer Care® award winner in Melanoma and Other Skin Cancers, Caroline Robert, MD, PhD, has helped clarify the role of immune therapies in advanced melanoma with her groundbreaking work on clinical trials evaluating anti– CTLA-4 and anti–PD-1 antibodies.

Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases

September 6th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefit in BRAF-Mutant Melanoma

September 3rd 2019

Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.

Dr. Hurwitz on Patient Cohorts in the PIVOT-02 Trial

August 30th 2019

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.

Dr. Guminski on 16-Month Follow-Up With Cemiplimab in mCSCC

August 29th 2019

Alexander Guminski, MD, PhD, medical oncologist, Royal North Shore Hospital, University of Sydney, discusses the 16-month follow-up results of a phase II trial evaluating cemiplimab (Libtayo) in patients with metastatic cutaneous squamous cell carcinoma.

Dr. Long on the Results of the Pooled Analysis of the COMBI-i Trial in Melanoma

August 28th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses the results of the pooled analysis of parts 1 and 2 of the phase III COMBI-i study.

Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial

August 27th 2019

Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma.

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

August 22nd 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses data from a phase I trial exploring the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma.

Checkpoint Inhibitors Vault Into Frontline Settings Across Tumor Types

August 6th 2019

By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve patient outcomes.

NY-ESO-1 Gains Momentum as a Therapeutic Target

August 2nd 2019

As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.

FDA Grants Bempegaldesleukin Plus Nivolumab Breakthrough Designation in Melanoma

August 1st 2019

The FDA granted a breakthrough therapy designation to the combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) for the treatment of patients with previously untreated unresectable or metastatic melanoma.

Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma

August 1st 2019

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy and director of clinical research, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the rationale to explore triplet therapy in BRAF V600-mutant melanoma.

Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma

August 1st 2019

Paul D. Nathan, MBBS, PhD, FRCP, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib plus trametinib in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Novel Therapies for BRAF+ Colorectal Cancer

July 31st 2019

Treating BRAF+ Colorectal Cancer

July 31st 2019

Targeting BRAF and MEK in Colorectal Cancer

July 31st 2019

BRAF Mutations in Colorectal Cancer

July 31st 2019

Emerging Treatment Strategies for Advanced BRAF+ Melanoma

July 31st 2019

Sequencing Therapy in Metastatic BRAF+ Melanoma

July 31st 2019

Selecting Therapy & Managing Patients With BRAF+ Melanoma

July 31st 2019